MedTrace Logo

Pharmacokinetics and Safety Profile of CKD-333

NCT03659149 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2018-10-31

No results posted yet for this study

Summary

Compare the pharmacokinetic characteristics and safety between CKD-333 tablet and CKD-330, D086 combination

Conditions

Interventions

DRUG

CKD-333 formulation I

1 tablet administered before the breakfast(single-dose)

DRUG

CKD-333 formulation II

1 tablet administered before the breakfast(single-dose)

DRUG

CKD-330+D086

2 tablet administered before the breakfast(single-dose)

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Seunghun Han, Ph.D. · Department of Clinical Pharmacology, Seoul ST.Mayr's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-08
Primary Completion
2018-10-05
Completion
2018-10-12

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659149 on ClinicalTrials.gov